RESEARCH ARTICLE


Multicentric Reticulohistiocytosis Treated Successfully with Etanercept



C. Rodríguez-Cerdeira*, 1, B. Sánchez-Blanco1, San Millán B2, J.J. Vilata3
1 Dermatology Department, CHUVI & University of Vigo, Vigo, Spain
2 Pathology Department, CHUVI, Vigo, Spain
3 Dermatology Department, University of Valencia, Valencia, Spain

Article Information


Identifiers and Pagination:

Year: 2008
Volume: 2
First Page: 44
Last Page: 47
Publisher ID: TODJ-2-44
DOI: 10.2174/1874372200802010044

Article History:

Received Date: 04/03/2008
Revision Received Date: 02/04/2008
Acceptance Date: 07/04/2008
Electronic publication date: 29/4/2008
Collection year: 2008

Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 458
Abstract HTML Views: 1148
PDF Downloads: 1028
Total Views/Downloads: 2634
Unique Statistics:

Full-Text HTML Views: 281
Abstract HTML Views: 745
PDF Downloads: 628
Total Views/Downloads: 1654



Creative Commons License
© 2008 Rodríguez-Cerdeira et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, CHUVI, Meixoeiro Hospital & University of Vigo, 36200 Vigo, Galicia, Spain; Tel: 0034600536114; Fax: 0034986276416; E-mail:Carmen.Rodriguez.Cerdeira@sergas.es or aristoteles_cerdeira@yahoo.es


Abstract

Multicentric reticulohistiocytosis (MRH) is an uncommon systemic disease of unknown aetiology, which is characterized by the presence of papulonodular lesions, and is caused by the proliferation of histiocytes associated with arthritis. There are only just 200 cases described in the scientific literature. It can behave like a paraneoplasia and may be malignant in a quarter of the patients. We would like to add our patient to those described in the literature. Our patient was a 68 year-old male stonemason who was diagnosed of multicentric reticulohistiocytosis and was previously unsuccessfully treated with classical immunosupressants. The patient did, nonetheless, develop favourably with etanercept, with remission of the clinical and articular lesions.

In our opinion we feel that new treatment hopes will emerge for the treatment of inflammatory diseases where tumoral necrosis factor (TNF)-alpha and other cytokine production by monocytes and macrophages will play an important role.

Keywords: Multicentric reticulohistiocytosis, TNF-alpha, etanercept.